Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.83 |
| ▸ | JAK2 | O60674 | 8/20 | 0.70 |
| ▸ | JAK1 | P23458 | 7/20 | 0.70 |
| ▸ | STAT6 | P42226 | 1/20 | 0.70 |
| ▸ | TYK2 | P29597 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261158 | 1.00 | JAK3 (0.83) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL29622786 | 0.91 | JAK3 (0.83) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL22261166 | 0.91 | JAK3 (0.83) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL29622849 | 0.89 | JAK3 (0.81) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL22261148 | 0.89 | JAK3 (0.81) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL22261091 | 0.88 | JAK3 (0.80) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL29622811 | 0.88 | JAK3 (0.80) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL22261289 | 0.88 | JAK3 (0.83) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL29622795 | 0.88 | JAK3 (0.83) | JAK3JAK2JAK1STAT6TYK2 | |
| SCHEMBL22261057 | 0.88 | JAK3 (0.81) | JAK3JAK2JAK1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |